462 results on '"Sadelain M"'
Search Results
2. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
3. Immunotherapy: DISCOVERY PROTEOMICS FOR ANALYTES TO PREDICT CYTOKINE RELEASE SYNDROME ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
4. Genetic ablation of adhesion ligands effectively averts rejection of allogeneic immune cells
5. Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells
6. 46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
7. Lentiviral globin gene therapy with reduced intensity conditioning in adults with severe beta-thalassemia
8. PREDICTORS FOR NEUROTOXICITY on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform
9. Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring γ-retrovirus-encoded hsvtk suicide genes
10. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories
11. Insertional oncogenesis in gene therapy: how much of a risk?
12. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
13. Establishing cGMP manufacturing of CRISPR/Cas9-edited human CAR T cells
14. Adenovirus facilitated infection of human cells with ecotropic retrovirus
15. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes
16. Basic Principles of Gene Transfer in Hematopoietic Stem Cells
17. Globin gene transfer as a potential treatment for the β-thalassaemias and sickle cell disease
18. Immuno gene therapy comes into its own
19. Imaging Transgene Expression for Gene Therapy
20. MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY
21. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
22. S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
23. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
24. A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma.
25. A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
26. Radiation Sensitizes Tumor Cells to CAR T Cell Immunotherapy
27. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections
28. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity
29. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy
30. Soluble and membrane-bound interleukin (IL)-15 R α/IL-15 complexes mediate proliferation of high-avidity central memory CD8 + T cells for adoptive immunotherapy of cancer and infections.
31. CARs, CCRs and iCARs: A new class of drugs for cancer immunotherapy
32. Highly Divergent Integration Profile of Adeno-Associated Virus Serotype 5 Revealed by High-Throughput Sequencing
33. Gene therapy of haemoglobinopathy: An Italy-USA project
34. Trail Over-Expression on Donor T Cells Enhances GVT and Suppresses GVHD by Inhibiting Alloreactive T Cells and Impairing Host APC Functions
35. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells.
36. Mesothelin Expression Promotes An Aggressive Phenotype Of Non-Small Cell Lung Cancer (NSCLC)
37. Genetically Engineered Donor T Cells for BMT Immunotherapy: Expression of Trail and PLZF Selectively Enhances GVT and Abrogates GVHD
38. In vitro analysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor.
39. Over-Expression Of Trail On Donor T Cells Simultaneously Ameliorates GVHD And Enhances GVT
40. Gene therapy of haemoglobinopathy: An Italy-USA project
41. A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19
42. Towards the genetic treatment of -thalassemia: new disease models, new vectors, new cells
43. 344: Off-the-Shelf Tumor Immunotherapy with Genetically Enhanced Allogeneic T-Cell Precursors
44. A Panel of Artificial Antigen-Presenting Cells (AAPC) Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Subdominant and Dominant Viral Epitopes for Adoptive Therapy.
45. In vitro expansion of CMV-specific CD4+ T-cells by artificial antigen presentation for adoptive immunotherapy in the post- transplant setting
46. Fetal gene therapy of -thalassemia in a mouse model
47. Xenogeneic immunization with tyrosinase DNA vaccines: results from clinical trials in humans and dogs
48. 268. CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo
49. 313. Cell Type Specific Media Optimization for Clinical Retroviral Transduction Protocols
50. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.